Dear Members,
Your Directors are pleased to present the thirty-eighth Annual Report and the audited
financial statements for the financial year ended March 31,2026.
FINANCIAL RESULTS
(Rs. in Crore)
| Particulars |
2025-26 |
2024-25 |
| Income from Operations |
1,482.51 |
1,356.36 |
| Profit before tax |
246.02 |
216.32 |
| Provisions for Tax |
62.40 |
55.33 |
| Profit for the year |
183.62 |
160.99 |
| Earnings per share |
20.03 |
17.56 |
RESULTS OF OPERATIONS
During the year under review, the income from operations of the Company grew by 9.3% to
Rs. 1,482.51 Crore against Rs. 1,356.36 Crore in the previous year.
The profit before tax increased by 14% to Rs. 246.02 Crore as compared to Rs. 216.32
Crore in the previous year. The profit after tax also increased by 14% to Rs. 183.62 Crore
as compared to Rs. 160.99 Crore in the previous year.
MATERIAL CHANGES AND COMMITMENTS AFFECTING THE COMPANY
No material changes and commitment affecting the financial position of the Company,
have occurred between the financial year ended on March 31,2026, and the date of the
report. There has been no change in the nature of business of the Company.
DIVIDEND
The Board of Directors has recommended a dividend of Rs. 4.0 per equity share (40% on
face value of Rs. 10 per share) on the paid-up equity share capital of the Company for the
financial year ended March 31, 2026, amounting to Rs. 36.67 Crore, which if approved, at
the forthcoming Annual General Meeting on September 24, 2026, will be paid within 30 days
from the date of AGM, to the Members whose names appear in the Register of Members, as on
September 18, 2026, being the record date fixed for this purpose. In respect of shares
held in electronic form, the dividend will be paid on the basis of beneficial ownership
furnished by the depositories viz., NSDL and CDSL for this purpose.
The dividend recommended is in accordance with the Company's Dividend Distribution
Policy.
In view of the changes made under the Income-tax Act, 2025, dividends paid or
distributed by the Company shall be taxable in the hands of the shareholders. Your Company
shall, accordingly, make the payment of the dividend after deduction of tax at source.
DIVIDEND DISTRIBUTION POLICY
Pursuant to Regulation 43A of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 [SEBI Listing Regulations], the
Board of Directors of the Company had formulated a Dividend Distribution Policy (the
Policy'). The Policy is available on the Company's website at https:// www.apollohospitals.com/region/delhi/pdf/Dividend-
Distribution-Policy.pdf
TRANSFER TO RESERVES
The Company does not propose to transfer any amount to general reserve on declaration
of dividend. The Board of Directors has decided to retain the entire amount of profits for
2025-26 in the distributable retained earnings.
SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES
The Company has no subsidiaries or associate companies. Also, it does not have any
joint venture operation with any other entity.
THE STATE OF COMPANY AFFAIRS
The Hospital remained committed to providing world class quality healthcare and
services. Focus continued on improving operational efficiencies across functions,
improving patient services and enhancing safety for patients and staff.
During the year under review, several complex procedures
were performed by our team of clinicians, bringing respite to
many chronically ill patients and their families.
The following rare procedures were performed at the
Indraprastha Apollo Hospital:
1. First Rezum therapy for the treatment of BPH was carried out smoothly, marking a
significant advancement in minimally invasive urological care.
2. India's first leadless pacemaker (dual chamber) implantation through a metallic
prosthetic tricuspid was performed on a 65 year old patient with a complex cardiac
history, including mechanical tricuspid valve replacement, developed symptomatic
bradyarrhythmia requiring pacingwhere conventional options were high-risk or
unfeasible. The procedure provided effective pacing and immediate symptom relief, marking
a significant breakthrough in cardiac care.
3. A 41 year old patient had an L4-L5 disc prolapse along with a coexisting intradural
tumor at the same levelan extremely uncommon presentation with only six such cases
reported worldwide. The patient presented with lowback pain radiating to the right lower
limb for a duration of 2 months. A month after the onset of symptoms, the pain started to
radiate to the left lower limb as well. Both conditions were successfully treated in a
single surgery, and the patient was discharged without any motor neurological deficit.
4. A 45-year-old patient with ESRD and neurogenic bladder, successfully underwent
simultaneous living donor kidney transplantation and ileal conduit formation. Despite
complex preoperative and postoperative challenges, the patient had an uneventful recovery
with excellent graft function.
5. A 14 year old girl from Nigeria with sickle cell disease, presented with severe left
hip pain and functional disability due to advanced avascular necrosis of the femoral head,
successfully underwent a left dualmobility uncemented total hip arthroplasty with
meticulous perioperative sickle cell precautions. Preoperative optimisation included
exchange blood transfusion to significantly reduce HbS levels before surgery.
Postoperative care was managed by a multidisciplinary team, and she was discharged pain-
free, ambulating comfortably with support.
6. A 77 year old female patient with recurrent left breast invasive ductal carcinoma
(triple-negative)
and significant comorbidities, including hypertrophic obstructive cardiomyopathy,
underwent successful ultrasound-guided percutaneous Cryoablation under local anesthesia.
The ice ball completely encompassed the 1.5 cm lesion with adequate margins and no
immediate complications. The procedure and postprocedure course were uneventful, and the
patient was discharged the following day. Cryoablation was performed using
freeze-thaw-freeze cycles, resulting in formation of an ice ball completely encompassing
the lesion and sufficient margin.
7. A Valve-in-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) was performed in
a patient with a prior Bio-Bentall procedure, marking the first such case described in
medical literature. A 72-year-old female with a degenerating bio-prosthetic aortic valve
and Chronic residual descending aortic dissection was successfully treated using a 23 mm
Navitor Vision (Abbott) valve through a highly complex, trans-femoral access route. The
procedure was completed over 3.5 hours with excellent outcomesthe patient was
discharged in stable condition. This case is being presented at PCR London Valves 2025,
the world's largest conference for trans-catheter heart valve therapies.
Further, a novel HLA allele identified by Transplant Immunology laboratory of the
Hospital, has been officially recognised and established by the WHO HLA Nomenclature
Committee and assigned the designation HLA-B*56:106, with inclusion in the IPD-IMGT/HLA
Database. This achievement reflects the high technical expertise and quality standards of
our team and further strengthens our institution's standing in the field of immunogenetics
and transplantation diagnostics at national and international levels.
On a Public Interest Litigation (PIL) regarding free treatment in the hospital, the
Hon'ble Delhi High Court vide its order dated September 22, 2009, has held that free
treatment provided by the hospital shall be inclusive of medicines & medical
consumables.
The Company has filed a Special Leave Petition (SLP) before the Hon'ble Supreme Court
of India challenging the order of the Hon'ble Delhi High Court. The Hon'ble Supreme Court
has admitted the SLP and has passed an interim order on November 30, 2009, pursuant to
which, the Company has been providing free treatment to the patients referred by the
Government of NCT of Delhi and has been charging only for medicines & medical
consumables. The financial impact in the matter can be quantified only after the final
decision by the Hon'ble Supreme Court of India.
The Directorate of Health Services, Government of NCT of Delhi, has appointed a Nodal
Officer to be permanently stationed in the Hospital to support, guide and monitor the
treatment of patients referred by the Government.
The Company has moved an Interlocutory Application before the Hon'ble Supreme Court
seeking direction that the conditions relating to provision of free treatment facilities
for patients belonging to indigent category to the extent of 10% IPD and 25% OPD be made
applicable to the Company as have been made applicable in case of other hospitals.
Additionally, the Company has also made representations before the Government of NCT of
Delhi to allow the Company to extend free treatment including medicines and consumables up
to 10% IPD and 25% OPD as applicable to other hospitals.
During the year, a total of 48,737 patients (43,655 Out Patients and 5,082 In Patients)
were treated under the free category.
Accreditation
Healthcare accreditation is one of the major steps towards improving quality and
patient safety. Indraprastha Apollo Hospitals was the first hospital in the country to get
Joint Commission International (JCI) accreditation in the year 2005. It has been
reaccredited for the seventh time in December, 2023.This milestone is a testament to our
commitment to maintaining the highest standards of patient care and safety.
CORPORATE GOVERNANCE
The Company is committed to maintain the highest standards of corporate governance and
adhere to the corporate governance requirements set out by SEBI. The report on corporate
governance as required under the Listing Regulations, forms an integral part of this
report. The requisite certificate from Mr. Baldev Singh Kashtwal, Practicing Company
Secretary, confirming the compliance with the conditions of corporate governance is
attached to the report on Corporate Governance.
MANAGEMENT DISCUSSION AND ANALYSIS REPORT
Management Discussion and Analysis Report for the year under review, as stipulated
under Listing Regulations, forms an integral part of this report.
BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT
As stipulated under the SEBI Listing Regulations, the Business Responsibility and
Sustainability Report forms part of this Annual Report. The report outlines the
initiatives taken by the Company from an environmental, social and governance perspective
and is part of the Annual Report.
SEXUAL HARASSMENT POLICY
The Company has adopted a policy on prevention, prohibition and redressal of sexual
harassment at the workplace in line with the provisions of the Sexual Harassment of Women
at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed
thereunder. The Company has an Internal Complaints Committee (ICC) for providing a
redressal mechanism pertaining to sexual harassment of women employees at the work place.
The following is a summary of sexual harassment complaints received and disposed off
during the year:
| S. No |
Particulars |
Status of the No. of complaints received and disposed off |
| 1. |
Number of complaints on Sexual harassment received |
1 |
| 2. |
Number of Complaints disposed off during the year |
1 |
| 3. |
Number of cases pending for more than ninety days |
None |
| 4. |
Number of workshops or awareness programme against sexual harassment carried out |
The Company regularly conducts necessary awareness programmes for its employees. No.
of Workshops in Delhi-203 No. of Workshops in Noida-80 |
| 5. |
Nature of action taken by the employer or district officer |
None |
VIGIL MECHANISM/WHISTLE BLOWER POLICY
The Company has established a vigil mechanism for Directors and Employees to report
their genuine concerns, the details of which are given in the Corporate Governance Report.
The Whistle Blower Policy may be accessed on the Company's website on the https://cdn.apollohospitals .
com/delhi/2024/Whistle-Blower-Policy.pdf During the year, no matter or incident has been
received under the Whistle Blower Policy of the Company.
PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED
During the year, the Company has not given any loan or made an investment, nor given
any guarantee in terms of Section 186 of the Companies Act, 2013.
FIXED DEPOSITS
During the year, your company did not accept any deposits or renew existing deposits
from the public. The total outstanding deposits with the Company as on March 31, 2026, is
Nil.
DIRECTORS AND KEY MANAGERIAL PERSONNEL
Board Composition and Independent Directors
As at the end of the day on March 31, 2026, the Board consisted of four Non-Executive -
Non-Independent Directors, one Executive Director and eight Independent Directors.
Independent directors are appointed, based on the recommendation of the Nomination and
Remuneration Committee, for a term of five years and are not liable to retire by rotation.
In the opinion of the Board, the Independent Directors fulfil the conditions specified in
the Listing Regulations and are independent of the management.
All Independent Directors have given their declarations that they meet the criteria of
independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation
16(b) of the SEBI Listing Regulations.
In the opinion of the Board, the Independent Directors possess the requisite expertise
and experience and are persons of high integrity and repute. They fulfill the conditions
specified in the Act and the Listing Regulations and they are independent of the
management.
Retirement by Rotation
Pursuant to Section 152 of the Companies Act 2013, Prof. (Dr.) Mahesh Verma and Dr.
Suneeta Reddy, Directors, retire by rotation at the ensuing Annual General Meeting and
being eligible, have offered themselves for re-appointment. Based on the outcome of the
performance evaluation process, the Board recommends their reappointment. The notice
convening the AGM, to be held on September 24, 2026, sets out the relevant details.
Change in Board Composition
Dr. Menaka Guruswamy (DIN 08742679) completed her tenure viz. first term of five (5)
consecutive years on May 22, 2025, as Independent Director on the Board of Directors of
the Company. Owing to her professional commitments and law practice as a Senior Advocate
at the Supreme Court of India, she opted not to renew her second term as an Independent
Director on the Board of Directors of the Company. Consequently, she ceased to be the
Independent Director of the Company.
Dr. Arun Rai (DIN 07159822) completed his tenure viz. second term of five (5)
consecutive years on May 25, 2025, as Independent Director on the Board of Directors of
the Company. Consequently, he ceased to be the Director of the Company.
Mr. Sudhir Jalan (DIN 00111118) has been appointed as Independent Director of the
Company, for a period of 5 consecutive years effective from August 6, 2025 to August 5,
2030.
Mr. Harsh Pati Singhania (DIN 00086742) has been appointed as Independent Director of
the Company, for a period of 5 consecutive years effective from February 3, 2026 to
February 2, 2031.
Ms. Vineeta Rai (DIN 07013113) completed her tenure viz. first term of five (5)
consecutive years on February 7, 2026 and was re-appointed as an Independent Director for
the second term of five (5) consecutive years effective from February 8, 2026 to February
7, 2031.
Mr. Salil Singhal (DIN 00006629) completed his tenure viz. first term of five (5)
consecutive years on February 7, 2026 and was re-appointed as an Independent Director for
the second term of five (5) consecutive years effective from February 8, 2026 to February
7, 2031.
Mr. Vinayak Chatterjee (DIN 00008933) completed his tenure viz. second term of five (5)
consecutive years on March 31,2026, as Independent Director on the Board of Directors of
the Company. Consequently, he ceased to be the Director of the Company.
Ms. Madhumita Ganguli (DIN 00676830) completed her tenure viz. first term of five (5)
consecutive years on June 8, 2026 and was re-appointed as an Independent Director for the
second term of five (5) consecutive years effective from June 9, 2026 to June 08, 2031.
The Company is yet to get nomination from the Govt, of NCT of Delhi for appointment of
3 Directors including Chairman of the Company.
The Board places on record its appreciation for the invaluable contribution and
guidance given by Dr. Menaka Guruswamy, Dr. Arun Rai and Mr. Vinayak Chatterjee as
Independent Directors of the Company.
Key Managerial Personnel
Pursuant to the provisions of Section 203 of the Companies Act, 2013, the Key
Managerial Personnel of the Company are Mr. Shivakumar Pattabhiraman - Managing Director,
Mr. C. P. Tyagi - Chief Financial Officer and Mr. Priya Ranjan - Associate Vice President
- Corporate Affairs & Legal. There has been no change in the Key Managerial Personnel
during the year.
Board Evaluation
Pursuant to the provisions of the Companies Act, 2013, and in terms of Regulation
17(10) oftheSEBI Listing Regulations, the Board has carried out an annual performance
evaluation of its own performance, the Directors individually as well as the working of
the Committees. The manner in which the evaluation has been carried out has been
enumerated in the Corporate Governance Report.
NOMINATION & REMUNERATION POLICY
The Board has, on the recommendation of the Nomination and Remuneration Committee,
approved a policy for selection and appointment of Directors, Senior Management team and
their remuneration. Note on the Remuneration Policy is mentioned in the Corporate
Governance Report.
MEETINGS OF THE BOARD
The Board met five times during the financial year, the details of which are given in
the Corporate Governance Report. The intervening gap between the Meetings was within the
period prescribed under the Companies Act, 2013, read with the Listing Regulations.
RISK MANAGEMENT
The Board of Directors has constituted a Risk Management Committee to identify elements
of risk in different areas of operations and to develop a policy for actions associated to
mitigating the risks. The Committee on a timely basis informed the members of the Board
about risk assessment and minimisation procedures. In the opinion of the Committee, there
was no risk that may threaten the existence of the Company. The details of the Risk
Management Committee are included in the Corporate Governance Report.
INTERNAL FINANCIAL CONTROLS AND THEIR ADEQUACY
The Company has an Internal Control System, commensurate with the size, scale and
complexity of its operations.
The Internal Audit function reports to the Audit Committee to maintain its objectivity
and independence. Details of the internal control system and its terms of reference are
set out in the Management Discussion and Analysis Report forming part of the Board's
Report.
The Board of Directors has laid down internal financial controls to be followed by the
Company and the policies and procedures to be adopted by the Company for ensuring the
orderly and efficient conduct of its business, including adherence to the Company's
policies, the safeguarding of its assets, prevention and detection of frauds and errors,
the accuracy and completeness of the accounting records, and the timely preparation of
reliable financial information. The Audit Committee evaluates the internal financial
control systems periodically.
SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
There are no significant material orders passed by the Regulators / Courts which would
impact the going concern status of the Company and its future operations.
DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to Section 134(5) of the Companies Act 2013, the Board of Directors, to the
best of their knowledge, hereby state and confirm:
a. that in the preparation of the annual financial statements for the year ended March
31, 2026, the
applicable accounting standards have been followed along with proper explanations
relating to material departures, if any;
b. that such accounting policies have been selected and applied consistently, and
judgement and estimates have been made that are reasonable and prudent so as to give a
true and fair view of the state of affairs of the Company as at March 31,2026, and of the
profit of the Company for the year ended on that date;
c. that proper and sufficient care has been taken for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013, for
safeguarding the assets of the Company and for preventing and detecting fraud and other
irregularities;
d. that the annual financial statements have been prepared on a going concern basis;
e. that proper internal financial controls were in place and that the financial
controls were adequate and were operating effectively;
f. that systems to ensure compliance with the provisions of all applicable laws were in
place and were adequate and operating effectively.
SHARE CAPITAL
The paid-up Equity Share Capital as on March 31, 2026, was Rs. 91.67 Crore.
During the year under review, the Company has not issued shares with differential
voting rights nor granted stock options nor sweat equity. As of March 31,2026 the details
of shareholding in the Company held by the Directors are set out in the Corporate
Governance Report forming part of the Board's Report.
EMPLOYEE STOCK OPTIONS
No Employee Stock Options have been granted to the employees of the Company and thus no
disclosure is required.
CREDIT RATINGS
During the year ended March 31,2026, ICRA Limited has reaffirmed :
a) Long-Term - Fund Based / Term Loan - credit rating of [ICRAjAA (stable)] for Rs.
92.50 crore;
b) Long-Term - Fund Based / Cash Credit - credit rating of [ICRAjAA(stable) for Rs.
40.00 crore; and
c) Short Term - Non-Fund Based - credit rating of [ICRA] A1+ for Rs. 30.00 crore, to
the Company
CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES
All contracts/arrangements/transactions entered by the Company during the financial
year with related parties were in the ordinary course of business and on an arm's length
basis and approved by the Audit Committee.
During the year, the Company has not entered into any contract / arrangement /
transaction with related parties which could be considered material in accordance with the
policy of the Company on materiality of related party transactions. Since, there were no
material transactions of the Company with any of its related parties, disclosure of the
Related Party Transactions as required under Section 134(3)(h) of the Companies Act, 2013,
in AOC-2 is not applicable to the Company.
The details of RPTs during the financial year, including transactions with person or
entities belonging to the promoter/ promoter group which hold(s) 10% or more shareholding
in the Company are provided in the accompanying financial statements.
The policy on materiality of related party transactions as
approved by the Board may be accessed on the Company's
website at https://cdn.apollohospitals.com/delhi/2024/
Policy-on-Related-Party-Transaction.pdf
Your directors draw the attention of the members to Notes
to the financial statements which sets out related party
disclosures.
During the financial year, the Independent Directors of the Company had no pecuniary
relationship or transactions with the Company other than sitting fees, commission and
reimbursement of expenses, as applicable.
PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES
Disclosure pertaining to remuneration and other details as required under Section
197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 is annexed to the Report as Annexure -1.
Statement containing particulars of top 10 employees and particulars of employees as
required under Section 197 (12) of the Act read with Rule 5(2) and (3) of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided as a
separate Annexure forming part of this report.
In terms of proviso to Section 136(1) of the Act, the Report and Accounts are being
sent to the Shareholders, excluding the aforesaid Annexure. The said Statement is also
open for inspection. Any member interested in obtaining a copy of the same may write to
the Company Secretary.
INDUSTRIAL RELATIONS
The Industrial Relations continued to be cordial during the year under review.
CORPORATE SOCIAL RESPONSIBILITY INITIATIVES
In terms of the provisions of Section 135 of the Act read with the Companies (Corporate
Social Responsibility Policy) Rules, 2014, the Board of Directors of the Company have
constituted a Corporate Social Responsibility and Sustainability ("CSRS")
Committee. As part of its initiatives under CSR, the Company has focused and undertaken
projects in the areas of Rural Development, Healthcare, Education & Skill Development
and Research in Healthcare. These projects are in accordance with Schedule VII of the
Companies Act, 2013. The Report on CSR activities for the financial year 2025-2026 is
annexed herewith marked as Annexure - 2 to this Report.
STATUTORY AUDITORS
The Members at the Annual General Meeting held on September 23, 2022, had approved the
re-appointment of Statutory Auditors of your Company namely, M/s S.N. Dhawan & Co.,
LLP, Chartered Accountants, for the second and final term of five consecutive years, to
hold office from the conclusion of the 34th Annual General Meeting till the conclusion of
the 39th Annual General Meeting to be held in the year 2027.
The Report given by Statutory Auditors on the financial statement of the Company for
the financial year 2025-26 forms part of the Annual Report. The Notes on the financial
statements referred to in the Auditors' Report are self- explanatory and do not call for
any further comments.
The Auditors' Report on the financial statements of the Company for the financial year
ended March 31, 2026,
is unmodified i.e. it does not contain any qualification, reservation or adverse
remark.
COST AUDITORS
Pursuant to Section 148 of the Companies Act, 2013, read with the Companies (Cost
Records and Audit) Amendment Rules, 2014, the Directors on the recommendation of the Audit
Committee, appointed M/s Devarajan Swaminathan and Co., Cost Accountants (FRN 100669), to
audit the cost accounts of the Company for the financial year 2026-27 on a remuneration of
Rs. 6.50 Lacs.
As required under the Companies Act, 2013, the remuneration payable to the Cost Auditor
is required to be placed before the members in a general meeting for their ratification.
Accordingly, a resolution seeking member's ratification for the remuneration payable to
M/s Devarajan Swaminathan and Co., Cost Accountants (FRN 100669), is included at Item No.
5 of the Notice convening the Annual General Meeting.
The Company has maintained cost records in accordance with the provisions of the
Companies Act, 2013, read with the Companies (Cost Records and Audit) Amendment Rules,
2014, in respect of healthcare services.
SECRETARIAL AUDITORS
The Members at the Annual General Meeting held on September 24, 2025, had approved the
appointment of Secretarial Auditors of your Company namely, M/s RSM & Co., Peer
Reviewed Firm of Practicing Company Secretaries, for a period of five consecutive years
commencing from Financial Year 2025-26 to 2029-30.
Secretarial Auditors Report
The Secretarial Audit Report for the financial year ended March 31, 2026, is annexed
herewith marked as Annexure - 3, to this Report.
During the period under review, the Company has complied with the provisions of the
Act, Rules, Regulations, Guidelines, Standards etc. and the same is covered under the
Secretarial Audit Report, save and except that:
(i) the Govt, of NCT of Delhi - one of the promoters of the Company, have not
dematerialized their shareholding in the Company. Requests have been made by the Company
to the Govt, of NCT of Delhi to get their shareholding dematerialized; and
(ii) appointment / re-appointment of Mr. Sudhir Jalan, Ms. Vineeta Rai & Mr. Salil
Singhal, who had attained the age of 75 years and above, as Independent Directors of the
Company without obtaining prior approval of the Shareholders.
Internal Auditors
The Board of Directors of the Company based on the recommendations of the Audit
Committee, appointed M/s SCV & Co. LLP., as Internal Auditors to conduct Internal
Audit of the Company for a period up to September 30, 2027.
Board's response on Auditor's qualification, reservation or adverse remarks or
disclaimer made.
The Directors hereby confirm that there are no qualifications, reservations or adverse
remark made by the statutory auditors of the company or in the secretarial audit report by
the practicing company secretary and secretarial compliance report for the year ended
March 31, 2026, save and except that the Govt, of NCT of Delhi - one of the promoters of
the Company, have not dematerialised their shareholding in the Company. Requests have been
made by the Company to the Govt, of NCT of Delhi to get their shareholding dematerialised.
REPORTING OF FRAUDS BY AUDITORS
During the year under review, neither the statutory auditors nor the secretarial
auditors has reported to the Audit Committee, under Section 143 (12) of the Companies Act,
2013, any instances of fraud committed against the Company by its officers or employees.
OTHER DISCLOSURES:
a) During the year, the Company had complied with the applicable, Secretarial Standards
relating to "Meetings of the Board of Directors" and "General
Meetings".
b) There are no proceedings initiated/pending against the Company under the Insolvency
and Bankruptcy Code, 2016, which materially impact the business of the Company.
c) There were no instances where the Company required the valuation for one time
settlement or while taking loans from the Banks or Financial Institutions.
d) During the year there has been no change in the nature of business of the Company.
PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN I
EXCHANGE EARNINGS AND OUTGO.
Information as required to be disclosed on conservation of energy, technology
absorption and foreign exchange earnings and outgo stipulated under Section 134(3)
(m) of the Companies Act, 2013, read with Rule 8 of the Companies (Accounts) Rules,
2014, is annexed herewith marked as Annexure - 4 to this Report.
ANNUAL RETURN
In accordance with the provisions of Section 92(3) read with section 134(3)(a) of the
Companies Act, 2013, and Rules framed thereunder, an annual return in the prescribed
format for the financial year 2025-26 is available on the website of the Company at https://www.apollohospitals .
com/region/delhi/investor-relations/
ACKNOWLEDGEMENT
Your Directors wish to place on record their appreciation of the contribution made by,
the consultant doctors and the employees at all levels, towards the continued growth and
prosperity of your Company.
Your Directors also wish to place on record their appreciation of the Government of NCT
of Delhi, business constituents, bankers and other financial institutions and shareholders
of the Company for their continued support.
| For and on behalf of the Board of Directors |
| Dr. Prathap C. Reddy |
| Vice Chairman |
| (DIN 00003654) |
| Place : Chennai |
| Date : August 06, 2026 |
|